Contact Us | Home
Toll Free No. for USA/Canada:   1-866-279-8368
| Advance Search
 
Currency:  Ä $ £
Discounted Reports
MARKET RESEARCH SECTOR IN FOCUS
Energy & Resources
FMCG & Retailing
Pharmaceuticals and Healthcare
Textiles
MARKET REPORT DETAIL

Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2013

Enquire | Email | Print

ISBN: GMDHC4187IDB
Published Date: Oct, 2013
Format: PDF
No of Pages: 134
 
 
Select pricing :
Change Currency: Ä EURO | $ USD | £ GBP
Buy through us and save. We do not add any Tax / Duty including VAT,GST
  • Abstract
  • Table of Contents

Summary

'Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2013', provides an overview of the indicationís therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma. Cutaneous T-Cell Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directís proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directís team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cutaneous T-Cell Lymphoma.
- A review of the Cutaneous T-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cutaneous T-Cell Lymphoma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cutaneous T-Cell Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cutaneous T-Cell Lymphoma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Johnson & Johnson
Kyowa Hakko Kirin Co., Ltd.
Seattle Genetics, Inc.
Emergent BioSolutions Inc.
Millennium Pharmaceuticals, Inc.
Novartis AG
Eisai Co., Ltd.
Galderma S.A.
Onyx Pharmaceuticals, Inc.
Mundipharma International Limited
Innate Pharma SA
Spectrum Pharmaceuticals, Inc.
Chipscreen Biosciences Ltd
Mondobiotech Holding AG
Yaupon Therapeutics, Inc.
ELORAC, Inc.




Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Cutaneous T-Cell Lymphoma Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Cutaneous T-Cell Lymphoma 9
Cutaneous T-Cell Lymphoma Therapeutics under Development by Companies 11
Cutaneous T-Cell Lymphoma Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Cutaneous T-Cell Lymphoma Therapeutics - Products under Development by Companies 18
Cutaneous T-Cell Lymphoma Therapeutics - Products under Investigation by Universities/Institutes 19
Companies Involved in Cutaneous T-Cell Lymphoma Therapeutics Development 20
Johnson & Johnson 20
Kyowa Hakko Kirin Co., Ltd. 21
Seattle Genetics, Inc. 22
Emergent BioSolutions Inc. 23
Millennium Pharmaceuticals, Inc. 24
Novartis AG 25
Eisai Co., Ltd. 26
Galderma S.A. 27
Onyx Pharmaceuticals, Inc. 28
Mundipharma International Limited 29
Innate Pharma SA 30
Spectrum Pharmaceuticals, Inc. 31
Chipscreen Biosciences Ltd 32
Mondobiotech Holding AG 33
Yaupon Therapeutics, Inc. 34
ELORAC, Inc. 35
Cutaneous T-Cell Lymphoma - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
brentuximab vedotin - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
panobinostat - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
HBI-8000 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
bortezomib - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
carfilzomib - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
everolimus - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
mogamulizumab - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
forodesine hydrochloride - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
pralatrexate - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
IPH-41 Program - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
zanolimumab - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
quisinostat - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
naloxone hydrochloride - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
DNA IL-12 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
SHP-141 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Angeloxin - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
CD-5789 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Genetically Modified T Cells-1138 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
K-777 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Cutaneous T-Cell Lymphoma Therapeutics - Drug Profile Updates 85
Cutaneous T-Cell Lymphoma Therapeutics - Discontinued Products 122
Cutaneous T-Cell Lymphoma Therapeutics - Dormant Products 123
Cutaneous T-Cell Lymphoma - Product Development Milestones 125
Featured News & Press Releases 125
Aug 26, 2013: Ceptaris Receives FDA Approval for VALCHLOR Gel for the Treatment of Stage IA and IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma in Patients Who Have Received Prior Skin-Directed Therapy 125
Aug 08, 2013: FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma 126
Jul 24, 2013: Inovio Pharmaceuticals' Potent hTERT DNA Cancer Vaccine Shows Potential to Reduce Tumors and Prevent Tumor Recurrence 126
Jul 19, 2013: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab 128
Apr 12, 2013: Elorac's Naloxone Topical Lotion Receives FDA Fast Track Designation For Relief Of Pruritus In Patients With Cutaneous T-cell Lymphoma 128
Mar 04, 2013: Shape Pharma Provides Update On SHP-141 Topical HDAC Inhibitor Clinical Development For Cutaneous T Cell Lymphoma 129
Feb 27, 2013: Ceptaris Resubmits New Drug Application To FDA For Gel Formulation Of Mechlorethamine Hydrochloride 129
Dec 13, 2012: Kyowa Hakko Kirin Initiates Pivotal Phase III Trial Of Mogamulizumab In Patients With Cutaneous T-Cell Lymphoma In US 130
Dec 11, 2012: Kyowa Hakko Kirin Announces Presentation Of Phase II Clinical Trial Results Of Mogamulizumab At ASH Annual Meeting 130
Dec 10, 2012: Seattle Genetics Presents Data From Two Phase II Studies Of Adcetris In Cutaneous T-Cell Lymphoma At ASH Annual Meeting 131
Appendix 133
Methodology 133
Coverage 133
Secondary Research 133
Primary Research 133
Expert Panel Validation 133
Contact Us 134
Disclaimer 134

List of Tables
Number of Products Under Development for Cutaneous T-Cell Lymphoma, H2 2013 9
Products under Development for Cutaneous T-Cell Lymphoma - Comparative Analysis, H2 2013 10
Number of Products under Development by Companies, H2 2013 12
Number of Products under Investigation by Universities/Institutes, H2 2013 13
Comparative Analysis by Late Stage Development, H2 2013 14
Comparative Analysis by Mid Clinical Stage Development, H2 2013 15
Comparative Analysis by Early Clinical Stage Development, H2 2013 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 17
Products under Development by Companies, H2 2013 18
Products under Investigation by Universities/Institutes, H2 2013 19
Johnson & Johnson, H2 2013 20
Kyowa Hakko Kirin Co., Ltd., H2 2013 21
Seattle Genetics, Inc., H2 2013 22
Emergent BioSolutions Inc., H2 2013 23
Millennium Pharmaceuticals, Inc., H2 2013 24
Novartis AG, H2 2013 25
Eisai Co., Ltd., H2 2013 26
Galderma S.A., H2 2013 27
Onyx Pharmaceuticals, Inc., H2 2013 28
Mundipharma International Limited, H2 2013 29
Innate Pharma SA, H2 2013 30
Spectrum Pharmaceuticals, Inc., H2 2013 31
Chipscreen Biosciences Ltd, H2 2013 32
Mondobiotech Holding AG, H2 2013 33
Yaupon Therapeutics, Inc., H2 2013 34
ELORAC, Inc., H2 2013 35
Assessment by Monotherapy Products, H2 2013 36
Assessment by Stage and Route of Administration, H2 2013 38
Assessment by Stage and Molecule Type, H2 2013 40
Cutaneous T-Cell Lymphoma Therapeutics - Drug Profile Updates 85
Cutaneous T-Cell Lymphoma Therapeutics - Discontinued Products 122
Cutaneous T-Cell Lymphoma Therapeutics - Dormant Products 123
Cutaneous T-Cell Lymphoma Therapeutics - Dormant Products (Contd..1) 124

List of Figures
Number of Products under Development for Cutaneous T-Cell Lymphoma, H2 2013 9
Products under Development for Cutaneous T-Cell Lymphoma - Comparative Analysis, H2 2013 10
Products under Development by Companies, H2 2013 11
Products under Investigation by Universities/Institutes, H2 2013 13
Late Stage Products, H2 2013 14
Mid Clinical Stage Products, H2 2013 15
Early Clinical Stage Products, H2 2013 16
Discovery and Pre-Clinical Stage Products, H2 2013 17
Assessment by Monotherapy Products, H2 2013 36
Assessment by Route of Administration, H2 2013 37
Assessment by Stage and Route of Administration, H2 2013 38
Assessment by Molecule Type, H2 2013 39
Assessment by Stage and Molecule Type, H2 2013 40




Related Reports:  

 

Custom Research
If above report doesn't have the business information suitable for your business, we can provide custom research that would be lucrative for your business or enhance your profession. We leverage most comprehensive, affordable, high-quality custom research which will match exact topic & specifications of your choice. Please visit Custom Research page to make an enquiry.

 

Top Go to top of the page

product id: 433639, price: INR 121808, Global Markets Direct

International Travel Grant for Members of
MANLIBNET (Management Libraries Network)
We accept
Phone: +91.22.27810772, 27810773
E-mail: info@bharatbook.com
Hours: Mon to Sat 8:00 AM to 8:00 PM IST
Call USA/Canada 1-866-279-8368
 
GPlus
About Trust Online